Pirtobrutinib
Small molecule
Also known as LOXO-305, LY3527727
Evidence outlook
Approved: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Multiple Myeloma · Phase 1 · investigational in the US
Also approved (3)
- Jaypirca (pirtobrutinib) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, all lines of therapy regardless of prior covalent BTK inhibitor treatment
- Treatment of relapsed or refractory mantle cell lymphoma with resistance or intolerance to other BTK inhibitors
- Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
BRUIN CLL-321 NCT04666038 · Chronic Lymphocytic Leukemia Patients were randomised 1:1 against active standard options and the primary endpoint, independently assessed progression-free survival, was met (hazard ratio 0.536, p=0.0002) in 238 patients. The trial was open-label, so patients and clinicians knew the assigned treatment, and the comparator was a mix of two regimens with crossover allowed after progression. Registry: NCT04666038 | 3 | Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)) 2023-08-29 | Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Arm A - Pirtobrutinib 13.96 Months (95% CI 11.24 to 16.56) | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab 8.74 Months (95% CI 8.08 to 10.38) | Partial signal | link ↗ |
View 2 more trials
BRUIN-CLL-313 NCT05023980 · Chronic Lymphocytic Leukemia Registry: NCT05023980 | 3 | Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC) (From randomization until documented disease progression or death (up to 40 months)) 2025-07-11 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | not yet graded | link ↗ |
NCT03740529 NCT03740529 · Mantle Cell Lymphoma Registry: NCT03740529 | 1/2 | Maximum Tolerated Dose (MTD) (Up to 24 Months); Recommended dose for further study (Up to 24 Months); To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC). (Up to 24 months); To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0 (Up to 24 Months); To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0 (Up to 24 Months) 2025-01-27 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (42)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Competitive landscape
Other BTK drugs
Acalabrutinib, Ibrutinib, rilzabrutinib, zanubrutinib. Compare all 5 BTK drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pirtobrutinib: this drug | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Acalabrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Approved | Small molecule | BTK | Partial signal | NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | Partial signal | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Approved(overall) | Small molecule | BTK | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Venetoclax | Approved | Small molecule | BCL-2 | Partial signal | NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Partial signal | NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). | |
| Bexobrutideg | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Nemtabrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 2/3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1/2 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(49 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Pirtobrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (9)
February 2027 (1)
What to watch
April 2027 (1)
What to watch
July 2027 (2)
August 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (20)
January 2028 (1)
What to watch
February 2028 (2)
April 2028 (2)
June 2028 (2)
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (4)
January 2029 (1)
What to watch
May 2029 (1)
What to watch
August 2029 (1)
What to watch
October 2029 (1)
What to watch
2030 (8)
February 2030 (1)
What to watch
May 2030 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (3)
June 2031 (1)
What to watch
July 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (2)
2034 (1)
November 2034 (1)
What to watch
2035 (1)
October 2035 (1)
What to watch
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent